Osteoarthritis
Paradigm is developing injectable pentosan polysulfate sodium, Zilosul®, for knee osteoarthritis. It is a molecule with decades of existing safety data, for a disease where no available treatment alters its course, and it is in Phase 3 with an independent interim analysis targeted for September 2026.
Phase 3 Development Program
PARA_OA_012 is a multicentre, randomised, double-blind, placebo-controlled study of injectable pentosan polysulfate sodium in knee osteoarthritis. It is fully enrolled and closed to new participants.
- Status
- Fully enrolled, closed to new participants
- Study code
- PARA_OA_012
- Registry
- NCT06917404
- Design
- Multicentre, randomised, double-blind, placebo-controlled
- Primary endpoint
- Change from baseline in weekly average pain at Day 112
- Designation
- FDA Fast Track, April 2022
Milestones
The next milestone is an independent interim analysis, targeted for September 2026. Following database lock, a Data Safety Monitoring Board reviews the accumulated data. An earlier safety review of approximately 20% of completed participants identified no material safety concerns and recommended the trial continue without changes.
- Oct 2021 IND cleared by the US FDA Complete
- Apr 2022 FDA Fast Track designation Complete
- May 2025 First participant dosed Complete
- Jun 2026 Enrolment complete, 538 participants dosed Complete
- Next Sep 2026 Independent interim analysis Targeted
- Q1 2027 Topline results Expected
Key osteoarthritis figures
- GLOBAL
Following the osteoarthritis programme
Paradigm’s Phase 3 trial is fully enrolled and closed to new participants. Paradigm is not recruiting for any osteoarthritis trial at this time, and cannot discuss individual eligibility or any matter relating to your condition. Your own doctor is the right person to talk to about treatment options.
Trial details are published in full on the registries, and every milestone is announced to the ASX.